Table of Contents
SRX Medicine
Volume 2010, Article ID 973413, 5 pages
http://dx.doi.org/10.3814/2010/973413
Clinical Study

Long-Term Effect of Colestimide on Glycemic Control in Patients with Type 2 Diabetes with Elevated Low-Density Lipoprotein Cholesterol Levels

Department of Internal Medicine, Dokkyo Medical University Koshigaya Hospital, Minami-Koshigaya, Koshigaya 343-8555, Japan

Received 12 October 2009; Revised 24 October 2009; Accepted 25 October 2009

Copyright © 2010 Kohzo Takebayashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Garg and S. M. Grundy, “Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial,” Annals of Internal Medicine, vol. 121, no. 6, pp. 416–422, 1994. View at Google Scholar
  2. F. J. Zieve, M. F. Kalin, S. L. Schwartz, M. R. Jones, and W. L. Bailey, “Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes,” Clinical Therapeutics, vol. 29, no. 1, pp. 74–83, 2007. View at Publisher · View at Google Scholar · View at PubMed
  3. H. E. Bays, R. B. Goldberg, K. E. Truitt, and M. R. Jones, “Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects,” Archives of Internal Medicine, vol. 168, no. 18, pp. 1975–1983, 2008. View at Publisher · View at Google Scholar · View at PubMed
  4. R. B. Goldberg, V. A. Fonseca, K. E. Truitt, and M. R. Jones, “Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy,” Archives of Internal Medicine, vol. 168, no. 14, pp. 1531–1540, 2008. View at Publisher · View at Google Scholar · View at PubMed
  5. V. A. Fonseca, J. Rosenstock, A. C. Wang, K. E. Truitt, and M. R. Jones, “Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy,” Diabetes Care, vol. 31, no. 8, pp. 1479–1484, 2008. View at Publisher · View at Google Scholar · View at PubMed
  6. T. Yamakawa, T. Takano, H. Utsunomiya, K. Kadonosono, and A. Okamura, “Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia,” Endocrine Journal, vol. 54, no. 1, pp. 53–58, 2007. View at Publisher · View at Google Scholar
  7. K. Takebayashi, M. Suetsugu, S. Matsumoto, Y. Aso, and T. Inukai, “Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia,” Southern Medical Journal, vol. 102, no. 4, pp. 361–368, 2009. View at Publisher · View at Google Scholar · View at PubMed
  8. K. Takebayashi, Y. Aso, and T. Inukai, “Initiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetes,” Metabolism, vol. 53, no. 6, pp. 693–699, 2004. View at Publisher · View at Google Scholar
  9. Japan Diabetes Society, Treatment Guide for Diabetes, Bunkodo, Tokyo, Japan, 2007.
  10. H. E. Bays and R. B. Goldberg, “The ‘forgotten’ bile acid sequestrants: is now a good time to remember?” American Journal of Therapeutics, vol. 14, no. 6, pp. 567–580, 2007. View at Publisher · View at Google Scholar · View at PubMed
  11. H. M. Colhoun, D. J. Betteridge, P. N. Durrington et al., “Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial,” The Lancet, vol. 364, no. 9435, pp. 685–696, 2004. View at Publisher · View at Google Scholar · View at PubMed